Thetford Mines, Quebec – November 8, 2019 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”) is pleased to announce that the debt settlement previously announced in its press release dated October 31, 2019 has been completed and the Corporation settled indebtedness to a creditor totalling $780,000 in exchange for the issuance of 2,600,000 Class A Shares of KDA (“Common shares”) at a price of $0.30 per Common share (the “Debt Settlement”).

Thetford Mines, Quebec – October 24, 2019 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”) is pleased to announce, following the results of its shareholders’ annual general meeting held yesterday, October 23, 2019 the appointment of Mr. Stan Bharti as a member of the board of directors of the Corporation (the “Board of Directors”).

Thetford Mines, Quebec – August 7, 2019 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”) is proud to announce that it has signed a letter of intent (“LOI”) with the shareholders of Consultandgrow Inc. (the “Shareholders”) on August 6, 2019 for the purchase of all the shares of Consultandgrow Inc. (“Consultandgrow”).

Thetford Mines, Quebec – July 18, 2019 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”) is pleased to announce that the private placement previously announced in its press releases dated December 17, 2018 and March 21, 2019 has been completed with accredited investors totaling 21,500,000 Class A shares (“Common shares”) at a price of $0.15 per Common share for total gross proceeds of $3,225,000 (the “Private Placement”).

Thetford Mines, Quebec – June 26, 2019 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”) is proud to announce that Dr. Giuseppe D’Aprano is appointed to the Corporation’s management team as Chief Scientific Officer (CSO) as of June 26, 2019.

Thetford Mines, Quebec – February 18, 2019 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”) is pleased to announce that the transaction with Strides Pharma Canada inc. (“Strides”) previously announced in its press releases dated December 4, 2018 and February 1st, 2019, according to which Strides acquired 80% of the issued and outstanding shares of its subsidiary Pharmapar Inc. (“Pharmapar”) has been completed.

Thetford Mines, Quebec – February 1st, 2019 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”) is proud to announce, as previously disclosed in its press release dated December 4, 2018, that it has entered into a share purchase agreement (the “Purchase Agreement”) with Strides Pharmaceuticals Canada Inc. (“Strides”) under which Strides agreed to acquire 80% of the issued and outstanding shares of Pharmapar Inc. (“Pharmapar”), a subsidiary of KDA specializing in the distribution of generic drugs, for four million Canadian dollars (CAN$4,000,000) (the “Sale Price”).

Thetford Mines, Quebec – December 4, 2018 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”) is proud to announce that it has signed a letter of intent (“LOI”) with Strides Pharma Global Pte Ltd. (“Strides”) for the sales of a majority stake in Pharmapar Inc. (“Pharmapar”), a division of KDA

Thetford Mines, Quebec – July 3, 2018 – KDA Group Inc. (TSXV: KDA) (“KDA Group” or the “Corporation”) is proud to announce that it has signed an agreement for the acquisition of 51% of CanNorth Medic Inc.